Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
US FDA approves Pfizer, Arvinas' breast cancer drug
12:37pm, Friday, 01'st May 2026
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' drug for a type of breast cancer.
Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)
04:18am, Friday, 24'th Apr 2026
Affymax (OTCMKTS:AFFY - Get Free Report) and Arvinas (NASDAQ: ARVN - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the str
Arvinas (ARVN) Expected to Announce Earnings on Thursday
04:04am, Thursday, 23'rd Apr 2026
Arvinas (NASDAQ: ARVN - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Arvinas to post earnings of ($0.94) per share an
JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN
04:45am, Wednesday, 08'th Apr 2026
JPMorgan Chase and Co. lifted its holdings in Arvinas, Inc. (NASDAQ: ARVN) by 475.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange C
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
03:56am, Thursday, 02'nd Apr 2026
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
04:21am, Wednesday, 11'th Mar 2026
Arvinas (NASDAQ: ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi.
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:30pm, Tuesday, 10'th Mar 2026
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
05:37pm, Tuesday, 24'th Feb 2026
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
10:41am, Tuesday, 24'th Feb 2026
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 24'th Feb 2026
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – –
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Monday, 23'rd Feb 2026
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou
50,000 Shares in Arvinas, Inc. $ARVN Bought by BML Capital Management LLC
04:22am, Monday, 23'rd Feb 2026
BML Capital Management LLC bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commissi
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
07:00am, Tuesday, 17'th Feb 2026
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
